论文部分内容阅读
采用 PCR-SSCP 对35例非小细胞肺癌(NSCLC)肿瘤切除组织的 P53基因5～8号外显子进行突变检测,对8号外显子同时采用 PCR-DGGE 进行突变检测。发现 NSCLC 中 P53突变率为65.7%。P53突变率在肿瘤细胞不同分化程度间有显著差异,低分化 NSCLC 的 P53突变率(89.5%)明显大于高、中分化的NSCLC(37.4%),虽然有纵膈淋巴结转移的 P53突变率(71.4%)高于无纵膈转移者(57.1%),但统计学上无显著差异。结果表明 P53基因突变在 NSCLC 的发生中起重要作用,但尚不能表明是一种公认的 NSCLC 预后判断指标。
PCR-SSCP was used to detect mutations in exons 5-8 of the P53 gene in 35 non-small cell lung cancer (NSCLC) tumor resection tissues. Simultaneous detection of mutations was performed in exon 8 using PCR-DGGE. The P53 mutation rate in NSCLC was found to be 65.7%. The mutation rate of P53 was significantly different among tumor cells. The rate of P53 mutation in poorly differentiated NSCLC (89.5%) was significantly higher than that of high and moderately differentiated NSCLC (37.4%), although there was a P53 mutation rate in mediastinal lymph node metastasis (71.4). %) was higher than those without mediastinal metastasis (57.1%), but there was no statistically significant difference. The results indicate that the mutation of P53 plays an important role in the occurrence of NSCLC, but it is still not a proven indicator of prognosis of NSCLC.